While most recent efforts have focused on optimizing antibody combinations (Lou and Cao, 2022), we chose to modify the natural ligand BAFF for TCE therapy because of its ability to bind multiple tumor antigens (Tagami et al., 2024; Ullah and Mackay, 2023). This evidence concerns the gene TNFSF13B and neoplasm.